Avenue Therapeutics, Inc. (NASDAQ:ATXI) Sees Large Decline in Short Interest

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the target of a large drop in short interest in August. As of August 15th, there was short interest totalling 47,200 shares, a drop of 5.0% from the July 31st total of 49,700 shares. Based on an average trading volume of 45,300 shares, the short-interest ratio is currently 1.0 days. Currently, 3.6% of the shares of the stock are short sold.

Avenue Therapeutics Trading Up 0.7 %

NASDAQ ATXI opened at $2.81 on Thursday. The firm has a market capitalization of $2.64 million, a price-to-earnings ratio of -0.36 and a beta of -0.17. The firm’s 50 day simple moving average is $2.98 and its 200 day simple moving average is $6.07. Avenue Therapeutics has a 1 year low of $2.25 and a 1 year high of $64.27.

Avenue Therapeutics (NASDAQ:ATXI) last posted its quarterly earnings data on Friday, August 9th. The company reported ($6.43) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($5.38).

Institutional Investors Weigh In On Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Armistice Capital LLC acquired a new position in shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,000 shares of the company’s stock, valued at approximately $262,000. Armistice Capital LLC owned 7.97% of Avenue Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 17.34% of the company’s stock.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.